SEC Form SC 13D filed by BiomX Inc.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

[Rule 13d-101]

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.l 3d-l (a) AND AMENDMENTS THERETO FILED PURSUANT TO§ 240.13D-2(a)

(Amendment No. )*

BiomX Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

09090D103

(CUSIP Number)

David Clark

Deerfield Management Company, L.P.

345 Park Avenue South, 12^th

Floor, New York,  

New York 10010

(212) 551-1600

With a copy to:

Jonathan D. Weiner, Esq.

Mark D. Wood, Esq.

Katten Muchin Rosenman LLP

50 Rockefeller Plaza

New York, New York 10020

(212) 940-8800

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 March 15, 2024

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of§§ 240.13d-l(e), 240.13d-l(f) or 240.13d-l(g), check the following bo ☐.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240. l 3d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

SCHEDULE 13D

SCHEDULE 13D

SCHEDULE 13D

SCHEDULE 13D

SCHEDULE 13D

This Schedule 13D is filed by (i) Deerfield Private Design Fund V, L.P. (“Deerfield Private Design V”), (ii) Deerfield Mgmt V, L.P. (“Deerfield Mgmt V”) (iii) Deerfield Healthcare Innovations Fund II, L.P. (“Deerfield HIF II”), (iv) Deerfield Mgmt HIF II, L.P. (“Deerfield Mgmt HIF II”), (v) Deerfield Management Company, L.P. (“Deerfield Management”), and (vi) James E. Flynn, a natural person (“Flynn,” and collectively with Deerfield Management, Deerfield Private Design V, Deerfield Mgmt V, Deerfield HIF II, Deerfield Mgmt HIF II, the “Reporting Person”), with respect to the Common Stock of BiomX Inc. Deerfield Private Design V and Deerfield HIF II are referred to herein, collectively, as the “Funds” and each as a “Fund.”

This Statement on Schedule 13D relates to the shares of common stock, par value $0.0001 per share (the “Common Stock”), of BiomX Inc., a Delaware corporation (the “Company”). The address of the Company’s principal executive offices is 22 Einstein St., Floor 4, Ness Ziona, Israel.

The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is attached hereto as Exhibit 99.1.

Prior to the Company’s acquisition of Adaptive Phage Therapeutics, Inc., a Delaware corporation (“APT”), by way of merger pursuant to which, among other things, APT merged with an into a wholly owned subsidiary of the Company (the “Merger”), each Fund purchased 13,333,333 shares (“Series B-1 Shares”) of Series B-1 Preferred Stock of APT. In addition, prior to the consummation of the Merger, each Fund converted a Secured Promissory Note issued by APT (as borrower) to such Fund with a stated principal amount of $1,083,333.22 (“Convertible Note”) into 3,649,101 shares (the “Note Conversion Shares”) of Series B-1 Preferred Stock of APT, pursuant to the terms of such Convertible Note and the Note Conversion and Cancellation Agreement by and among the APT, the Funds and other parties named therein.

As a result of the Merger, all of the Series B-1 Shares and Note Conversion Shares were cancelled and converted into an aggregate of (x) 6,110,098 shares (the “Merger Common Shares”) of Common Stock, (y) 26,980 shares (the “Merger Preferred Shares”) of the Company’s newly-designated Series X Non-Voting Convertible Preferred Stock, par value $0.0001 per share (“Series X Preferred Stock”), each share of which will be convertible (if at all) into 1,000 shares of Common Stock (subject to certain conditions, including the receipt of requisite stockholder approval, and limitations described below), and (z) warrants exercisable for an aggregate of 1,444,350 shares of Common Stock at an exercise price of $5.00 per share of Common Stock, which can be exercised (if at all) at any time after the approval of the Stockholder Approval Matters (as defined below) by the stockholders of the Company and will expire on January 28, 2027 (the “Merger Warrants”). The number of shares of Common Stock, the number of shares of Common Stock issuable upon conversion of Series X Preferred Stock (to the extent it becomes convertible), and the number of shares of Common Stock issuable upon exercise of the Merger Warrants (to the extent they become exercisable) acquired by each Fund upon closing of the Merger were:

Further, in connection with the Merger, on March 15, 2024, pursuant to that certain Securities Purchase Agreement (the “PIPE Purchase Agreement”), dated as of March 6, 2024, by and among the Company and the parties named therein, the Funds acquired an aggregate of 80,700 shares of Series X Preferred Stock (each share of which will be convertible (if at all) into 1,000 shares of Common Stock (subject to certain conditions, including the receipt of requisite stockholder approval, and limitations described below)) and warrants exercisable (if at all) for an aggregate of 40,350,000 shares of Common Stock (subject to certain conditions and limitations described below) (the “Private Placement Warrants”), at a combined purchase price of $231.10 per share of Series X Preferred Stock and accompanying Private Placement Warrant (such accompanying Private Placement Warrants being exercisable for 500 shares of Common Stock per share of Series X Preferred Stock purchased in the private placement). The number of shares of Common Stock issuable upon conversion of Series X Preferred Stock (to the extent it becomes convertible) and the number of shares of Common Stock issuable upon exercise of the Private Placement Warrants (to the extent they become exercisable) acquired by each Fund upon closing of the Private Placement were:

Except as otherwise indicated herein, Deerfield Private Design V and Deerfield HIF II utilized their respective working capital to purchase the shares of Common Stock reported herein. Shares of Common Stock beneficially owned by the Reporting Persons are or may be held from time to time by the applicable Fund in margin accounts established with their respective brokers or banks, and a portion of the purchase price for the Common Stock may have been obtained through margin borrowing. Common Stock positions held in margin accounts may be pledged as collateral security for the repayment of debt balances in the margin accounts.

The information set forth in Items 3 and 6 is incorporated herein by reference.

The Reporting Persons have acquired the shares reported herein for investment purposes.

In connection with the Merger, and as contemplated by the Merger Agreement, Jonathan Leff, a partner of Deerfield Management, was appointed to the board of directors of the Company, and continues to serve in such capacity.

The Reporting Persons may communicate with members of the board of directors, members of the Company’s management and/or shareholders of the Company from time to time with respect to potential investment and acquisition opportunities and the financing thereof (which may include discussions regarding debt and/or equity financing that could be provided, in whole or in part, by the Funds and/or affiliated funds), strategic and operational matters and such other matters as the Reporting Persons may deem appropriate from time to time. Such matters are likely to include plans or proposals specified in clauses (a) through (j) of Item 4 of the Form of Schedule 13D, but the Reporting Persons have made no determination to pursue, and may not pursue, any such plan or proposal.

Depending on various factors and subject to the obligations described herein, the Reporting Persons may take such actions with respect to their investments in the Company as they deem appropriate, including, without limitation, purchasing additional shares of Common Stock or other financial instruments related to the Company or selling some or all of their beneficial or economic holdings, engaging in hedging or similar transactions with respect to the securities relating to the Company and/or otherwise changing their intention with respect to any and all matters referred to in Item 4 of Schedule 13D.

Item 5. Interest in Securities of the Issuer.

(a)

Number of shares: 3,055,049 (comprised of shares held by Deerfield Private Design Fund V, L.P.)

Percentage of Shares: 5.53%*

Number of shares: 3,055,049

Percentage of Shares: 5.53%*

Number of shares: 3,055,049 (comprised of shares held by Deerfield Healthcare Innovations Fund II, L.P.) 

Percentage of Shares: 5.53%*

Number of shares: 3,055,049 

Percentage of Shares: 5.53%*

Number of shares: 6,110,098 (comprised of shares held by Deerfield Private Design Fund V, L.P. and Deerfield Healthcare Innovations Fund II, L.P.) 

Percentage of Shares: 11.06%*

Number of shares: 6,110,098 (comprised of shares held by Deerfield Private Design Fund V, L.P. and Deerfield Healthcare Innovations Fund II, L.P.)

Percentage of Shares: 11.06%*

*Throughout this report, the percentage of outstanding shares of Common Stock beneficially owned by the Reporting Persons reflects (i) 46,055,109 shares of Common Stock outstanding as of March 4, 2024, based on representations made by the Company in the Merger Agreement, plus (ii) 9,164,967 shares of Common Stock issued pursuant to the Merger Agreement.

(b)

Sole power to vote or direct the vote: 0

Shared power to vote or direct the vote: 3,055,049

Sole power to dispose or to direct the disposition: 0

Shared power to dispose or direct the disposition: 3,055,049

Sole power to vote or direct the vote: 0

Shared power to vote or direct the vote: 3,055,049

Sole power to dispose or to direct the disposition: 0

Shared power to dispose or direct the disposition: 3,055,049

Sole power to vote or direct the vote: 0

Shared power to vote or direct the vote: 3,055,049

Sole power to dispose or to direct the disposition: 0

Shared power to dispose or direct the disposition: 3,055,049

Sole power to vote or direct the vote: 0

Shared power to vote or direct the vote: 3,055,049

Sole power to dispose or to direct the disposition: 0

Shared power to dispose or direct the disposition: 3,055,049

Sole power to vote or direct the vote: 0

Shared power to vote or direct the vote: 6,110,098

Sole power to dispose or to direct the disposition: 0

Shared power to dispose or direct the disposition: 6,110,098

Sole power to vote or direct the vote: 0

Shared power to vote or direct the vote: 6,110,098

Sole power to dispose or to direct the disposition: 0

Shared power to dispose or direct the disposition: 6,110,098

Flynn is the managing member of the general partner of each of Deerfield Mgmt V and Deerfield Mgmt HIF II and Deerfield Management. Deerfield Mgmt V is the general partner of Deerfield Private Design Fund V, L.P.; Deerfield Mgmt HIF II is the general partner of Deerfield Healthcare Innovations Fund II, L.P.; and Deerfield Management is the investment manager of each Fund. Each Fund purchases, holds and sells securities and other investment products. Schedule A hereto sets forth information regarding persons referred in Instruction C to Schedule 13D.

Merger Warrants

The Merger Warrants may be exercised (for cash or to the extent a registration statement is not available for the resale of shares underlying the Merger Warrants, on a cashless (net) exercise basis), if at all, at any time following approval by the Company’s stockholders of certain matters (the “Stockholder Approval Matters”) specified in the Merger Agreement, including the issuance of Common Stock in connection with (i) the conversion of the Series X Preferred Stock issued pursuant to the Merger Agreement and the PIPE Purchase Agreement, (ii) the exercise of the Merger Warrants and (iii) the exercise of the Private Placement Warrants, and prior to their expiration on January 28, 2027. The exercise price of the Merger Warrants is $5.00 per share of Common Stock, subject to customary adjustments for stock dividends, stock splits, reclassifications and the like. The Merger Warrants are subject to a beneficial ownership limitation, which restricts the exercise of such warrants to the extent that, upon such exercise, the number of shares of common stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) “group” would exceed 9.99% of the total number of shares of Common Stock then outstanding.

The foregoing description of the Merger Warrants does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Warrant, the form of which is filed or incorporated by reference as Exhibit 1 to this Schedule 13D.

Private Placement Warrants

The Private Placement Warrants may be exercised (for cash or to the extent a registration statement is not available for the resale of shares underlying the Private Placement Warrants, on a cashless (net) exercise basis), if at all, at any time following approval by the Company’s stockholders of the Stockholder Approval Matters and prior to their expiration on the 24-month anniversary of the date on which they are first exercisable. The exercise price of the Private Placement Warrants is $0.2311 per share of Common Stock, subject to customary adjustments for stock dividends, stock splits, reclassifications and the like. The Private Placement Warrants are subject to a beneficial ownership limitation, which restricts the exercise of such warrants to the extent that, upon such exercise, the number of shares of Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) “group” would exceed 9.99% of the total number of shares of Common Stock then outstanding.

The foregoing description of the Private Placement Warrants does not purport to be complete and is qualified in its entirety by reference to the full text of the Private Placement Warrant, the form of which is filed or incorporated by reference as Exhibit 2 to this Schedule 13D.

Series X Preferred Stock; Certificate of Designation

The powers, preferences, rights, qualifications, limitations and restrictions applicable to the Series X Preferred Stock are governed by the Certificate of Designation of Preferences, Rights and Limitations of the Series X Preferred Stock (the “Certificate of Designation”), which was filed by the Company with the Secretary of State of the State of Delaware prior to the closing of the Merger.

Holders, including the Funds, of Series X Preferred Stock are entitled to receive dividends on shares of Series X Preferred Stock equal to, on an as-if-converted-to-Common-Stock basis, and in the same form as, dividends actually paid on shares of the Common Stock. The Series X Preferred Stock ranks on parity with the Common Stock as to distributions upon the liquidation, dissolution or winding up of the Company.

Except as set forth in the Certificate of Designation or as required by the Delaware General Corporation Law, the Series X Preferred Stock does not have voting rights. The Certificate of Designation prohibits the Company from taking certain actions, including (i) consummating a Fundamental Transaction (as defined in the Certificate of Designation), or (ii) reclassifying the outstanding Common Stock, in each case prior to obtaining the Conversion Approval (as defined below), without the affirmative vote or written approval, agreement or waiver of the holders of 70% of the then outstanding shares of the Series X Preferred Stock (the “Requisite Holders”).

The Certificate of Designation provides that, effective as of 5:00 p.m. Eastern time on the fourth (4th) Business Day after the date that the Corporation’s stockholders approve the conversion of the Series X Non-Voting Preferred Stock into shares of Common Stock in accordance with the listing rules of the NYSE American (the “Conversion Approval”), each share of Series X Preferred Stock will automatically convert into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series X Preferred Stock is prohibited from converting shares of Series X Preferred Stock into shares of Common Stock to the extent that, after giving effect to such conversion, the number of shares of Common Stock then beneficially owned by the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) “group” would exceed a specified percentage (established by the holder between 0% and 19.99%). Each Fund has elected to be subject to a 9.99% beneficial ownership limitation in accordance with the Certificate of Designation.

The Certificate of Designation further provides that if, as of the earlier to occur of (a) such time as the Parent Stockholders’ Meeting (as defined in the Merger Agreement) is ultimately concluded, or (b) 5:00 p.m. Eastern time on the date that is five (5) months after the initial issuance of the Series X Non-Voting Preferred Stock (the “Deadline Date”), (x) the shares of Series X Non-Voting Preferred Stock are not convertible into Common Stock as a result of the failure to obtain the requisite stockholder approval and (y) a written request by the Requisite Holders has been delivered to the Company, then the Company will be obligated, at the request of the Requisite Holders to pay, prior to any payment in satisfaction of any redemption rights of any other class or series of capital stock of the Company, an amount in cash equal to the Fair Value (as defined in the Certificate of Designation) of the shares of Series X Non-Voting Preferred Stock held by each holder thereof.

The foregoing summary of the Certificate of Designation is not complete and is qualified in its entirety by reference to the full text thereof, the form of which is filed or incorporated by reference as Exhibit 3 to this Schedule 13D.

Registration Rights Agreement

On March 6, 2024, in connection with the Merger and the Private Placement, the Funds entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the Company. Pursuant to the Registration Rights Agreement, the Company is required to prepare and file with the SEC within 45 calendar days following the consummation of the Private Placement (the “Filing Deadline”) a resale registration statement (the “Registration Statement”) with respect to (i) shares of Common Stock, Series X Preferred Stock and Merger Warrants issued pursuant to the Merger, (ii) shares of Series X Preferred Stock and Private Placement Warrants issued pursuant to the Private Placement and (iii) any shares of Common Stock issued or issuable upon (a) exercise of the Merger Warrants and the Private Placement Warrants or (b) conversion of shares of Series X Preferred Stock (the “Registrable Securities”). The Company agreed to use its commercially reasonable efforts to cause the Registration Statement to be declared effective by the SEC within 45 calendar days of the Filing Deadline (or within 75 calendar days if the SEC reviews the Registration Statement).

The foregoing summary of the Registration Rights Agreement is not complete and is qualified in its entirety by reference to the full text thereof, the form of which is filed or incorporated by reference as Exhibit 4 to this Schedule 13D.

Lock-up

Concurrently and in connection with the Merger and the Private Placement, each Fund entered into a lock-up agreement with the Company and APT, pursuant to which each Fund agreed, subject to limited exceptions, not to offer or sell, or engage in swap or similar transactions with respect to, the Merger Common Shares, the Merger Preferred Shares, the Merger Warrants and the shares of Common Stock issuable upon conversion or exercise or the Merger Preferred Shares or Merger Warrants (the “Lock-up Agreements”).

The foregoing summary of the Lock-up Agreements is not complete and is qualified in its entirety by reference to the full text thereof, the form of which is filed or incorporated by reference as Exhibit 5 to this Schedule 13D.

Exhibit Index

Exhibit 99.2 Power of Attorney (previously filed as Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn)

*Filed herewith

SIGNATURE

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: March 22, 2024

Schedule A

General Partner of Deerfield Mgmt V, L.P.

The general partner of Deerfield Mgmt V is J.E. Flynn Capital V, LLC. The address of the principal business and/or principal office of Deerfield Mgmt V and J.E. Flynn Capital V, LLC is 345 Park Avenue South, 12th Floor, New York, NY 10010.

General Partner of Deerfield Private Design Fund V, L.P.

The general partner of Deerfield Private Design Fund V is Deerfield Mgmt V. The address of the principal business and/or principal office of Deerfield Mgmt V and Deerfield Private Design Fund V is 345 Park Avenue South, 12th Floor, New York, NY 10010.

General Partner of Deerfield Mgmt HIF II, L.P.

The general partner of Deerfield Mgmt HIF II is J.E. Flynn Capital HIF II, LLC. The address of the principal business and/or principal office of Deerfield Mgmt HIF II and J.E. Flynn Capital HIF II, LLC is 345 Park Avenue South, 12th Floor, New York, NY 10010.

General Partner of Deerfield Healthcare Innovations Fund II, L.P.

The general partner of Deerfield Healthcare Innovations Fund II is Deerfield Mgmt HIF II. The address of the principal business and/or principal office of Deerfield Mgmt HIF II and Deerfield Healthcare Innovations Fund II is 345 Park Avenue South, 12th Floor, New York, NY 10010.

General Partner of Deerfield Management Company, L.P.

The general partner of Deerfield Management is Flynn Management LLC. The address of the principal business and/or principal office of Deerfield Management and Flynn Management LLC is 345 Park Avenue South, 12th Floor, New York, NY 10010.